Report cover image

Biopharmaceutical Licensing Market Forecasts to 2032 – Global Analysis By Deal Type (In-Licensing, Out-Licensing, Co-Development, Joint Venture, Manufacturing Licenses and Other Deal Types), Licensing Model (Exclusive License, Field-Limited License and No

Publisher Stratistics Market Research Consulting
Published Sep 15, 2025
Length 200 Pages
SKU # SMR20398624

Description

1 Executive Summary
2 Preface
2.1 Abstract
2.2 Stake Holders
2.3 Research Scope
2.4 Research Methodology
2.4.1 Data Mining
2.4.2 Data Analysis
2.4.3 Data Validation
2.4.4 Research Approach
2.5 Research Sources
2.5.1 Primary Research Sources
2.5.2 Secondary Research Sources
2.5.3 Assumptions
3 Market Trend Analysis
3.1 Introduction
3.2 Drivers
3.3 Restraints
3.4 Opportunities
3.5 Threats
3.6 Application Analysis
3.7 End User Analysis
3.8 Emerging Markets
3.9 Impact of Covid-19
4 Porters Five Force Analysis
4.1 Bargaining power of suppliers
4.2 Bargaining power of buyers
4.3 Threat of substitutes
4.4 Threat of new entrants
4.5 Competitive rivalry
5 Global Biopharmaceutical Licensing Market, By Deal Type
5.1 Introduction
5.2 In-Licensing
5.3 Out-Licensing
5.4 Co-Development
5.5 Joint Venture
5.6 Manufacturing Licenses
5.7 Other Deal Types
6 Global Biopharmaceutical Licensing Market, By Licensing Model
6.1 Introduction
6.2 Exclusive License
6.3 Field-Limited License
6.4 Non-Exclusive License
7 Global Biopharmaceutical Licensing Market, By Stage of Development
7.1 Introduction
7.2 Discovery & Preclinical Stage
7.3 Phase I
7.4 Phase II
7.5 Phase III
7.6 Commercialization/Marketed Product Stage
8 Global Biopharmaceutical Licensing Market, By Modality
8.1 Introduction
8.2 Monoclonal Antibodies (mAbs) & Biologics
8.3 Cell & Gene Therapies (CGT)
8.4 mRNA & Nucleic Acid Therapies
8.5 Vaccines
8.6 Small Biologics-Derived Molecules
8.7 Recombinant Proteins
8.8 Other Modalities
9 Global Biopharmaceutical Licensing Market, By Application
9.1 Introduction
9.2 Oncology
9.3 Immunology
9.4 Infectious Diseases
9.5 Cardiovascular Diseases
9.6 Neurological Diseases
9.7 Metabolic & Endocrine Diseases
9.8 Rare Diseases
9.9 Other Applications
10 Global Biopharmaceutical Licensing Market, By End User
10.1 Introduction
10.2 Biotech & Mid-Caps
10.3 Contract Research Organizations
10.4 Contract Development & Manufacturing Organizations
10.5 Academic & Research Institutes
10.6 Other End Users
11 Global Biopharmaceutical Licensing Market, By Geography
11.1 Introduction
11.2 North America
11.2.1 US
11.2.2 Canada
11.2.3 Mexico
11.3 Europe
11.3.1 Germany
11.3.2 UK
11.3.3 Italy
11.3.4 France
11.3.5 Spain
11.3.6 Rest of Europe
11.4 Asia Pacific
11.4.1 Japan
11.4.2 China
11.4.3 India
11.4.4 Australia
11.4.5 New Zealand
11.4.6 South Korea
11.4.7 Rest of Asia Pacific
11.5 South America
11.5.1 Argentina
11.5.2 Brazil
11.5.3 Chile
11.5.4 Rest of South America
11.6 Middle East & Africa
11.6.1 Saudi Arabia
11.6.2 UAE
11.6.3 Qatar
11.6.4 South Africa
11.6.5 Rest of Middle East & Africa
12 Key Developments
12.1 Agreements, Partnerships, Collaborations and Joint Ventures
12.2 Acquisitions & Mergers
12.3 New Product Launch
12.4 Expansions
12.5 Other Key Strategies
13 Company Profiling
13.1 Novartis
13.2 Pfizer
13.3 Roche
13.4 Johnson & Johnson
13.5 Merck & Co.
13.6 AstraZeneca
13.7 Sanofi
13.8 GlaxoSmithKline (GSK)
13.9 AbbVie
13.10 Bristol-Myers Squibb (BMS)
13.11 Amgen
13.12 Eli Lilly & Company
13.13 Takeda Pharmaceutical Company
13.14 Gilead Sciences
13.15 Regeneron Pharmaceuticals
13.16 Biogen
13.17 Vertex Pharmaceuticals
13.18 Moderna
13.19 Bayer AG
13.20 Incyte Corporation
List of Tables
Table 1 Global Biopharmaceutical Licensing Market Outlook, By Region (2024-2032) ($MN)
Table 2 Global Biopharmaceutical Licensing Market Outlook, By Deal Type (2024-2032) ($MN)
Table 3 Global Biopharmaceutical Licensing Market Outlook, By In-Licensing (2024-2032) ($MN)
Table 4 Global Biopharmaceutical Licensing Market Outlook, By Out-Licensing (2024-2032) ($MN)
Table 5 Global Biopharmaceutical Licensing Market Outlook, By Co-Development (2024-2032) ($MN)
Table 6 Global Biopharmaceutical Licensing Market Outlook, By Joint Venture (2024-2032) ($MN)
Table 7 Global Biopharmaceutical Licensing Market Outlook, By Manufacturing Licenses (2024-2032) ($MN)
Table 8 Global Biopharmaceutical Licensing Market Outlook, By Other Deal Types (2024-2032) ($MN)
Table 9 Global Biopharmaceutical Licensing Market Outlook, By Licensing Model (2024-2032) ($MN)
Table 10 Global Biopharmaceutical Licensing Market Outlook, By Exclusive License (2024-2032) ($MN)
Table 11 Global Biopharmaceutical Licensing Market Outlook, By Field-Limited License (2024-2032) ($MN)
Table 12 Global Biopharmaceutical Licensing Market Outlook, By Non-Exclusive License (2024-2032) ($MN)
Table 13 Global Biopharmaceutical Licensing Market Outlook, By Stage of Development (2024-2032) ($MN)
Table 14 Global Biopharmaceutical Licensing Market Outlook, By Discovery & Preclinical Stage (2024-2032) ($MN)
Table 15 Global Biopharmaceutical Licensing Market Outlook, By Phase I (2024-2032) ($MN)
Table 16 Global Biopharmaceutical Licensing Market Outlook, By Phase II (2024-2032) ($MN)
Table 17 Global Biopharmaceutical Licensing Market Outlook, By Phase III (2024-2032) ($MN)
Table 18 Global Biopharmaceutical Licensing Market Outlook, By Commercialization/Marketed Product Stage (2024-2032) ($MN)
Table 19 Global Biopharmaceutical Licensing Market Outlook, By Modality (2024-2032) ($MN)
Table 20 Global Biopharmaceutical Licensing Market Outlook, By Monoclonal Antibodies (mAbs) & Biologics (2024-2032) ($MN)
Table 21 Global Biopharmaceutical Licensing Market Outlook, By Cell & Gene Therapies (CGT) (2024-2032) ($MN)
Table 22 Global Biopharmaceutical Licensing Market Outlook, By mRNA & Nucleic Acid Therapies (2024-2032) ($MN)
Table 23 Global Biopharmaceutical Licensing Market Outlook, By Vaccines (2024-2032) ($MN)
Table 24 Global Biopharmaceutical Licensing Market Outlook, By Small Biologics-Derived Molecules (2024-2032) ($MN)
Table 25 Global Biopharmaceutical Licensing Market Outlook, By Recombinant Proteins (2024-2032) ($MN)
Table 26 Global Biopharmaceutical Licensing Market Outlook, By Other Modalities (2024-2032) ($MN)
Table 27 Global Biopharmaceutical Licensing Market Outlook, By Application (2024-2032) ($MN)
Table 28 Global Biopharmaceutical Licensing Market Outlook, By Oncology (2024-2032) ($MN)
Table 29 Global Biopharmaceutical Licensing Market Outlook, By Immunology (2024-2032) ($MN)
Table 30 Global Biopharmaceutical Licensing Market Outlook, By Infectious Diseases (2024-2032) ($MN)
Table 31 Global Biopharmaceutical Licensing Market Outlook, By Cardiovascular Diseases (2024-2032) ($MN)
Table 32 Global Biopharmaceutical Licensing Market Outlook, By Neurological Diseases (2024-2032) ($MN)
Table 33 Global Biopharmaceutical Licensing Market Outlook, By Metabolic & Endocrine Diseases (2024-2032) ($MN)
Table 34 Global Biopharmaceutical Licensing Market Outlook, By Rare Diseases (2024-2032) ($MN)
Table 35 Global Biopharmaceutical Licensing Market Outlook, By Other Applications (2024-2032) ($MN)
Table 36 Global Biopharmaceutical Licensing Market Outlook, By End User (2024-2032) ($MN)
Table 37 Global Biopharmaceutical Licensing Market Outlook, By Biotech & Mid-Caps (2024-2032) ($MN)
Table 38 Global Biopharmaceutical Licensing Market Outlook, By Contract Research Organizations (2024-2032) ($MN)
Table 39 Global Biopharmaceutical Licensing Market Outlook, By Contract Development & Manufacturing Organizations (2024-2032) ($MN)
Table 40 Global Biopharmaceutical Licensing Market Outlook, By Academic & Research Institutes (2024-2032) ($MN)
Table 41 Global Biopharmaceutical Licensing Market Outlook, By Other End Users (2024-2032) ($MN)
Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.

Table of Contents

200 Pages
1 Executive Summary 2 Preface 2.1 Abstract 2.2 Stake Holders 2.3 Research Scope 2.4 Research Methodology 2.4.1 Data Mining 2.4.2 Data Analysis 2.4.3 Data Validation 2.4.4 Research Approach 2.5 Research Sources 2.5.1 Primary Research Sources 2.5.2 Secondary Research Sources 2.5.3 Assumptions 3 Market Trend Analysis 3.1 Introduction 3.2 Drivers 3.3 Restraints 3.4 Opportunities 3.5 Threats 3.6 Application Analysis 3.7 End User Analysis 3.8 Emerging Markets 3.9 Impact of Covid-19 4 Porters Five Force Analysis 4.1 Bargaining power of suppliers 4.2 Bargaining power of buyers 4.3 Threat of substitutes 4.4 Threat of new entrants 4.5 Competitive rivalry 5 Global Biopharmaceutical Licensing Market, By Deal Type 5.1 Introduction 5.2 In-Licensing 5.3 Out-Licensing 5.4 Co-Development 5.5 Joint Venture 5.6 Manufacturing Licenses 5.7 Other Deal Types 6 Global Biopharmaceutical Licensing Market, By Licensing Model 6.1 Introduction 6.2 Exclusive License 6.3 Field-Limited License 6.4 Non-Exclusive License 7 Global Biopharmaceutical Licensing Market, By Stage of Development 7.1 Introduction 7.2 Discovery & Preclinical Stage 7.3 Phase I 7.4 Phase II 7.5 Phase III 7.6 Commercialization/Marketed Product Stage 8 Global Biopharmaceutical Licensing Market, By Modality 8.1 Introduction 8.2 Monoclonal Antibodies (mAbs) & Biologics 8.3 Cell & Gene Therapies (CGT) 8.4 mRNA & Nucleic Acid Therapies 8.5 Vaccines 8.6 Small Biologics-Derived Molecules 8.7 Recombinant Proteins 8.8 Other Modalities 9 Global Biopharmaceutical Licensing Market, By Application 9.1 Introduction 9.2 Oncology 9.3 Immunology 9.4 Infectious Diseases 9.5 Cardiovascular Diseases 9.6 Neurological Diseases 9.7 Metabolic & Endocrine Diseases 9.8 Rare Diseases 9.9 Other Applications 10 Global Biopharmaceutical Licensing Market, By End User 10.1 Introduction 10.2 Biotech & Mid-Caps 10.3 Contract Research Organizations 10.4 Contract Development & Manufacturing Organizations 10.5 Academic & Research Institutes 10.6 Other End Users 11 Global Biopharmaceutical Licensing Market, By Geography 11.1 Introduction 11.2 North America 11.2.1 US 11.2.2 Canada 11.2.3 Mexico 11.3 Europe 11.3.1 Germany 11.3.2 UK 11.3.3 Italy 11.3.4 France 11.3.5 Spain 11.3.6 Rest of Europe 11.4 Asia Pacific 11.4.1 Japan 11.4.2 China 11.4.3 India 11.4.4 Australia 11.4.5 New Zealand 11.4.6 South Korea 11.4.7 Rest of Asia Pacific 11.5 South America 11.5.1 Argentina 11.5.2 Brazil 11.5.3 Chile 11.5.4 Rest of South America 11.6 Middle East & Africa 11.6.1 Saudi Arabia 11.6.2 UAE 11.6.3 Qatar 11.6.4 South Africa 11.6.5 Rest of Middle East & Africa 12 Key Developments 12.1 Agreements, Partnerships, Collaborations and Joint Ventures 12.2 Acquisitions & Mergers 12.3 New Product Launch 12.4 Expansions 12.5 Other Key Strategies 13 Company Profiling 13.1 Novartis 13.2 Pfizer 13.3 Roche 13.4 Johnson & Johnson 13.5 Merck & Co. 13.6 AstraZeneca 13.7 Sanofi 13.8 GlaxoSmithKline (GSK) 13.9 AbbVie 13.10 Bristol-Myers Squibb (BMS) 13.11 Amgen 13.12 Eli Lilly & Company 13.13 Takeda Pharmaceutical Company 13.14 Gilead Sciences 13.15 Regeneron Pharmaceuticals 13.16 Biogen 13.17 Vertex Pharmaceuticals 13.18 Moderna 13.19 Bayer AG 13.20 Incyte Corporation List of Tables Table 1 Global Biopharmaceutical Licensing Market Outlook, By Region (2024-2032) ($MN) Table 2 Global Biopharmaceutical Licensing Market Outlook, By Deal Type (2024-2032) ($MN) Table 3 Global Biopharmaceutical Licensing Market Outlook, By In-Licensing (2024-2032) ($MN) Table 4 Global Biopharmaceutical Licensing Market Outlook, By Out-Licensing (2024-2032) ($MN) Table 5 Global Biopharmaceutical Licensing Market Outlook, By Co-Development (2024-2032) ($MN) Table 6 Global Biopharmaceutical Licensing Market Outlook, By Joint Venture (2024-2032) ($MN) Table 7 Global Biopharmaceutical Licensing Market Outlook, By Manufacturing Licenses (2024-2032) ($MN) Table 8 Global Biopharmaceutical Licensing Market Outlook, By Other Deal Types (2024-2032) ($MN) Table 9 Global Biopharmaceutical Licensing Market Outlook, By Licensing Model (2024-2032) ($MN) Table 10 Global Biopharmaceutical Licensing Market Outlook, By Exclusive License (2024-2032) ($MN) Table 11 Global Biopharmaceutical Licensing Market Outlook, By Field-Limited License (2024-2032) ($MN) Table 12 Global Biopharmaceutical Licensing Market Outlook, By Non-Exclusive License (2024-2032) ($MN) Table 13 Global Biopharmaceutical Licensing Market Outlook, By Stage of Development (2024-2032) ($MN) Table 14 Global Biopharmaceutical Licensing Market Outlook, By Discovery & Preclinical Stage (2024-2032) ($MN) Table 15 Global Biopharmaceutical Licensing Market Outlook, By Phase I (2024-2032) ($MN) Table 16 Global Biopharmaceutical Licensing Market Outlook, By Phase II (2024-2032) ($MN) Table 17 Global Biopharmaceutical Licensing Market Outlook, By Phase III (2024-2032) ($MN) Table 18 Global Biopharmaceutical Licensing Market Outlook, By Commercialization/Marketed Product Stage (2024-2032) ($MN) Table 19 Global Biopharmaceutical Licensing Market Outlook, By Modality (2024-2032) ($MN) Table 20 Global Biopharmaceutical Licensing Market Outlook, By Monoclonal Antibodies (mAbs) & Biologics (2024-2032) ($MN) Table 21 Global Biopharmaceutical Licensing Market Outlook, By Cell & Gene Therapies (CGT) (2024-2032) ($MN) Table 22 Global Biopharmaceutical Licensing Market Outlook, By mRNA & Nucleic Acid Therapies (2024-2032) ($MN) Table 23 Global Biopharmaceutical Licensing Market Outlook, By Vaccines (2024-2032) ($MN) Table 24 Global Biopharmaceutical Licensing Market Outlook, By Small Biologics-Derived Molecules (2024-2032) ($MN) Table 25 Global Biopharmaceutical Licensing Market Outlook, By Recombinant Proteins (2024-2032) ($MN) Table 26 Global Biopharmaceutical Licensing Market Outlook, By Other Modalities (2024-2032) ($MN) Table 27 Global Biopharmaceutical Licensing Market Outlook, By Application (2024-2032) ($MN) Table 28 Global Biopharmaceutical Licensing Market Outlook, By Oncology (2024-2032) ($MN) Table 29 Global Biopharmaceutical Licensing Market Outlook, By Immunology (2024-2032) ($MN) Table 30 Global Biopharmaceutical Licensing Market Outlook, By Infectious Diseases (2024-2032) ($MN) Table 31 Global Biopharmaceutical Licensing Market Outlook, By Cardiovascular Diseases (2024-2032) ($MN) Table 32 Global Biopharmaceutical Licensing Market Outlook, By Neurological Diseases (2024-2032) ($MN) Table 33 Global Biopharmaceutical Licensing Market Outlook, By Metabolic & Endocrine Diseases (2024-2032) ($MN) Table 34 Global Biopharmaceutical Licensing Market Outlook, By Rare Diseases (2024-2032) ($MN) Table 35 Global Biopharmaceutical Licensing Market Outlook, By Other Applications (2024-2032) ($MN) Table 36 Global Biopharmaceutical Licensing Market Outlook, By End User (2024-2032) ($MN) Table 37 Global Biopharmaceutical Licensing Market Outlook, By Biotech & Mid-Caps (2024-2032) ($MN) Table 38 Global Biopharmaceutical Licensing Market Outlook, By Contract Research Organizations (2024-2032) ($MN) Table 39 Global Biopharmaceutical Licensing Market Outlook, By Contract Development & Manufacturing Organizations (2024-2032) ($MN) Table 40 Global Biopharmaceutical Licensing Market Outlook, By Academic & Research Institutes (2024-2032) ($MN) Table 41 Global Biopharmaceutical Licensing Market Outlook, By Other End Users (2024-2032) ($MN) Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.

Pricing

Currency Rates
How Do Licenses Work?

How Do Licenses Work?

The primary function of a report license is to define how many people within a company are authorized to use the purchased report. This is separate to how a report might be delivered. Unless specifically identified otherwise, the purchase option is Single User. Below is a helpful description of that license, along with a sampling of others most commonly offered.

  • This license allows only one user to have access to and to use/read the report. It is not one user at a time or one user group; it is an individual who will be reading and utilizing the report.

  • This license allows for the entire purchasing company to read and use the report. This is the license level that would allow for a report to be placed on an internal company shared drive for access by all employees of that direct company. This license does not extend to parent or sister company use.

  • This license is designed to allow an entire department within a company full access to a report. The departmental license is a great option for companies that have more than one location and the department is spread out all over the country/world

  • This license is for companies that have one location where they want the report to be accessible by all employees within that physical location.

  • This is the most flexible of the licensing options. Some publishers will allow you to get a license for a preset number of people (typically 5). These licenses are ideal for small work groups.

License options are at the discretion of each publisher. As such, not all licenses indicated above are available for every product. If you are uncertain of the best license for your needs or would like a license that is not proactively available, please contact us and we will be happy to assist.

Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
Chat Now
Contact Us